Assisted Reproductive Technology (ART) Market Size by Procedure (Fresh Donor, Fresh Nondonor, Frozen Donor, Frozen Nondonor, Egg/Embryo bank), Industry Analysis Report, Regional Outlook (U.S, Canada, UK, France, Germany, Italy, Spain, China, India, Japan, Brazil, Mexico, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023

Industry Trends

Assisted Reproductive Technology (ART) Market size was USD 22.3 billion in 2015, and is anticipated to expand at 4.4% CAGR from 2016 to 2023 to be valued at USD 31.4 billion by 2023.
 

U.S. Assisted Reproductive Technology Market size by procedure, 2012-2023 (USD Million)

ART is an advanced technology which is used to treat infertility. The methods included in ART are In Vitro Fertilization (IVF), Intracytoplasmic sperm injection (ICSI), Gamete intrafallopian transfer (GIFT), and zygote intrafallopian transfer (ZIFT). IVF is the dominant technique, in which the sperm and the eggs are combined in a laboratory. The fertilized embryos (eggs) are transferred into a woman’s uterus; excess embryos are cryopreserved or frozen for the future. The IVF technology is used for many causes of infertility such as male factor and endometriosis or unexplained infertility is. IVF treatment cycle process includes ovarian stimulation, egg retrieval, fertilization, embryo culture, and embryo transfer. 
 

Ovarian stimulation is also known as ovarian induction; drugs are used to enhance eggs to grow in ovaries. Egg retrieval is accomplished by transvaginal ultrasound aspiration; minor surgical procedure can be performed at outpatient office or physician center. The eggs are retrieved from the follicles through a suction device. The extra embryos are cryopreserved for future transfer. The cryopreservation results in ART cycles being expensive, simpler, and less invasive than initial IVF cycle. Frozen embryos are stored for prolonged periods (up to 20 years).
 

Gamete intrafallopian transfer (GIFT) is a process in which the gametes are transferred into the woman’s fallopian tube rather than uterus, and fertilization occurs in fallopian tubes. GIFT can be performed only when the fallopian tubes are normal. GIFT comprises less than 1% of ART procedures in the U.S. Zygote intrafallopian transfer (ZIFT) differs from GIFT. The fertilization takes place in laboratory rather than fallopian tube. The fertilized egg is transferred to the tube rather than the uterus. ICSI is a process, in which sperm cell is directly injected into the matured egg. In the U.S, ICSI dominates ART procedures, approximately 60% of ART cycles are ICSI cycles.
 

Assisted Reproductive Technology (ART) Market, By Procedure

Fresh donor segment surpassed USD 1.3 billion in revenue in 2015, which is forecast to grow at over 5% CAGR from 2016 to 2023. ART cycles in which a woman uses her own eggs is most predominant among younger women; ART cycles using donor egg increases in proportion with age. According to the Centers for Disease Control and Prevention (CDC), the type of ART cycles varied by woman’s age. Majority of women (97%) younger than age 35 used their own eggs (nondonor), about 3% of women used donor eggs.
 

These embryos have been collected from one woman and frozen or cryopreserved, then transferred to another woman. The frozen nondonor segment is expanding at a significant CAGR of 5.8% over the forecast period. The frozen or cryopreserved embryo cycles are those previously preserved embryos are thawed and then transferred. The frozen embryo cycles formed from a previously simulated cycle, there is no need to retrieval in present cycle. However, the cycles are less invasive as well as less expensive than cycles with fresh embryos. Freezing few of embryos from a retrieval procedure enables increase probability of having a child from a single retrieval.
 

Assisted Reproductive Technology (ART) Market, By Region

Asia Pacific assisted reproductive technology market share accounted for over 19% of the global revenue, and will expand at 6.1% CAGR estimations from 2016 to 2023. Rapid rise in the healthcare infrastructure in countries such as China, India and Japan is expected to drive growth over the forecast timeline.
 

North America assisted reproductive technology market size was over USD 9 billion in 2015, and it is projected to be valued at more than USD 11 billion by 2023, expanding at a CAGR of 2.7% from 2016 to 2023.  Increase in the infertility due to obesity and demographical changes enables propel the North America assisted reproductive technology market. Europe assisted reproductive technology market size occupied over 22.5% of the revenue in 2015 and it is expected to grow at 5.6% CAGR over the forecast period.
 

Competitive Market share

Key industry players contributing to global assisted reproductive technology market share include Irvine Scientific, Origio a/s, Vitro Life, Esco Micro Pte. Ltd, IVFtech ApS, Cook Medical, Research Instruments, Genea Limited, Smiths Medical, Thermo Fisher Scientific, Inc.
 

Assisted Reproductive Technology (ART) Industry Background

Rise in the rapid advanced technologies and increased inclination towards innovative methods to treat infertility have driven the assisted reproductive technology market. Gradual increase in infertility prevalence is also a prime growth factor. Increased awareness among the general population has led to growing preference for these procedures. While developed regions dominate global revenue, Asia Pacific countries will provide lucrative opportunities for companies operating in the assisted reproductive technology market.
 

What Information does this report contain?